Purification And Characterization Of Hepatic Stimulator Substance

A major objective of clinical hepatology is to develop a successful method for the treatment of fulminant hepatic failure, a disease that has an extremely poor prognosis and carries a high mortality. Management of the disease is difficult and current hepatic support procedures available have been tried with very disappointed results. Since the prognosis of FHF dependes on the degree of both cell destruction and cell proliferation, one method for treating the patients is to prevent hepatic deterioration or accelerate regeneration of the damaged liver.In this paper, we present preliminary data on the purification and characterization of hepatic stimulator substance (HSS)-a new specific liver growth factor . The main subjects in this paper including:1. Crude HSS was extracted and separated from human fetal liver, porcine fetal liver and canine regenerating liver, and its biological activity was investigated by using growing weanling mice or 34% hepatectomized regenerating rats.2. The treatment of HSS in improving the survival of rats with acute liver failure induced by D-galactosamine (1.6 gm/kg BW) was observed, and the effects of HSS on alanine transaminase and endotoxin in the plasma, on lipid peroxides, ~3H-thymidine incorporation and histological changes in the liver of the poisoned rats administrated with sub-lethal dose D-galactosamine (1.2gm/kg BW) were evaluated.3. HSS was further purified by heating the human fetal liver homogenate in 35% Tris-HCl(w/v, 0.02M, pH7.4) at 95℃ for 20 min, high- and ultra-speed centrifugation, passage over sepadex G-100 gel filtration, DEAE-cellulose ion-exchange column, TSk G3000 SWG high performance liquid...